版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
Antibody(Ab)IntroductionAntibody(Ab)
proteinproducedbyplasmacellsinresponsetoimmunizationandbindsspecificallytoparticularAg.
1854-1917Nationality:GermanyFields:PhysiologyandimmunologyKnown
forDiphtheriavaccineNobelPrizeinPhysiologyormedicine(1901)for“Antitoxinimmunity”theory
EmilvonBehring(1845-1917)1901,antitoxinsNobelPrizewinnerexotoxins1937年,Tiselius和Kabat創(chuàng)建了血清蛋白電泳技術(shù),提出抗體就是
g球蛋白。Immunoglobulin1948RodneyPorter1917-1985NobelPrizein1972GeraldEdelman1929--NobelPrizein1972"fortheirdiscoveriesconcerningthechemicalstructureofantibodies"structureoftheAbHandLchainVandCRegionHingeregionDomainJchainandSPIgFragmentStructuresofAb四肽鏈二硫鍵“Y”1.HeavyChainandLightChain
heavychain(Hchain)50~75Kd450~550aaHchain(classes):
isotype:IgM,IgG,IgA,IgE,IgDIgG:IgG1~4IgA:IgA1,IgA2
StructureoftheAb1.HeavyChainandLightChain
lightchain(Lchain)
25Kd214aaclassesofLchain:
:1~42.variableregionandconstantregion
variableregion(Vregion)LightChain-VL(110aa)HeavyChain-VH(110aa)HVRorCDRFR
constantregion(Cregion)LightChain-CL(110aa)HeavyChain-CH(330-440aa):CH1,CH2,CH3,(CH4)StructuresofAb可變區(qū)和恒定區(qū)(VariableregionandConstantregion)VCdomain可變區(qū)和恒定區(qū)(VariableregionandConstantregion)高變區(qū)(hypervariableregion,HVR)/互補(bǔ)決定區(qū)(complementaritydeterminingregion,CDR)骨架區(qū)FrameworkregionsFR(frameworkregion)regionsbetweentheCDRsintheVregionarecalledtheFR.VLandVH:Agbindingsite鉸鏈區(qū)(hingeregion)CH1與CH2之間(IgM和IgE無)flexibility:allowthetwoFabarmstobindepitopeJ鏈(Joiningchain)分泌片(secretorypiece,SP)
木瓜蛋白酶水解片段:2Fab段+Fc段
胃蛋白酶水解片段:F(ab’)2段+pFc’段ProteolyiticFragmentofanIgGmoleculeHeterogeneityofAb1.ClassificationofIgclassμγαεδsubclassIgG1~IgG4type
subtype12
342.DiversityofIg
inducedbyexogenousfactors3.SerotypesofIginducedbyendogenousfactorsg鏈e鏈m鏈d鏈a鏈輕鏈Lightchain:k鏈和l鏈l鏈:l1、2、3、4HeterogeneityofAbIgG1IgG4IgG3IgG2免疫球蛋白的血清型(一)同種型(二)同種異型(三)獨(dú)特型isotypeIgCregionHumanantibodyRabbitantibodyallotype
(IgC
region)HumanantibodyHumanantibodyIdiotype(Id)(CDR)HumanantibodyHumanantibodyFunctionsofAbsFunctionsofAbsIgV
regionValency:結(jié)合抗原表位的個數(shù)。FunctionsofAbsAffinity=
attractiveandrepulsiveforcesAbAgHighAffinityAbAgLowAffinityAffinity(親和力)StrengthofthereactionbetweenasingleantigenicdeterminantandasingleAbcombiningsiteAvidity(親合力)TheoverallstrengthofbindingbetweenanAgwithmanydeterminantsandmultivalentAbsYKeq=104AffinityY106AvidityYYYYY1010AvidityreversalcombinationnoncovalentforcehydrogenbondelectrostaticattractionVanderWalsforces
hydrophobicbonddegreeofdissociationAg-AbaffinityEnvironmentalfactorsAsincreasingconcentrationsofAgareaddedtoaconstantamountofAb,theamountofICprecipitatedrisesandthenfalls.Theprecipitincurvegeneratedinthiswayhasthreezones.
Abexcesszone(prozone)equivalencezoneAgexcesszone(postzone)FactorsAffectingMeasurementofAg/AbReactionsAffinityAvidityAg:AbratioPhysicalformofAgAbexcessAgexcessEquivalence–Latticeformation(Visible)SmallcomplexSmallcomplexFunctionsofAbsFunctionofVregionBindingofantigensFunctionsofAbsFunctionofCregion1.activationcomplement:IgM,IgG1-3,IgA2.bindingtoFcreceptorofcells(1)opsonization:Aprocessbywhichphagocytosisisfacilitatedbythedepositionofopsonins(AborC3b)ontheantigen.
ActivatecomplementFunctionofIgOpsonizationofantibody(2)ADCC(Ab-dependentcell-mediatedcytotoxicity)AcytotoxicreactioninwhichFcreceptor-bearingkillercellsrecognizetargetcellsviaspecificantibodies.(3)IgEmediatestypeⅠhypersensitivityFunctionofimmunoglobulinsADCC
3.passagethroughtheplacenta(IgG)andmucosal(SIgA)穿過胎盤和黏膜ImmunityistransferredfrommothertofetusthroughplacentaltransferofIgG.CharacteristicandfunctionofDifferentclassofIgPage96Table5-2IgGimmunoglobulina)IgGisthemostimportantclassofIginserum-75%ofserumIghalf-lifeinserum:23daysb)Fixescomplement–IgG1-3canwhileIgG4cannotIgG3>IgG1>IgG2>IgG4c)crossestheplacentaconfersahighdegreeofpassiveimmunitytothenewborn.d)BindingtocellsMacrophages,monocytes,PMNandsomelymphocytesBindingtoSPANeutralizationofToxinbyIgGneutralizationofviralactivity
IgMimmunoglobulina)Penatmerb)IgMisthefirstIgsynthesizedinlifec)IgMisagoodcomplementfixingIgd)IgMisalsoagoodagglutinatingIge)IgMismIgM(IgD)ofBcells:f)IgMisthefirstIgproduced
inprimaryimmuneresponse.IgAimmunoglobulinIgA:monomerandsecretarysIgAexistsinsecretionssuchastears,saliva,colostrum,mucusandhasimportantroleinlocal(mucosal)immunity.c)IgAcanbetransmittedfrommothertonewbornIgEimmunoglobulinIgEistheleastserumIg.b)InvolvedintypeⅠallergicreactionsc)IgEplaysaroleinparasitichelminthdiseasesIgDimmunoglobulinIgDisfoundinlowlevelsinserum;itsroleinserumuncertain.b)IgDisprimarilyfoundonBcellsurfaceswhereitfunctionsasareceptorforantigen.MembraneIgDdisappearinactvatedormemoryBcellPreparationofAbs1)Polyclonalantibody2)Monoclonalantibody3)Geneticengineeringantibodymonoclonalantibody(mAb)針對單一抗原表位的高度均一的特異性IgGeorgesKohlerandCesarMilstein,1975,discoveredmonoclonalantibody1984immunoglobulinMonoclonalantibodyproductionGeneticengineeringantibodyGeneticengineeringantibodyFabantibodyFvantibodySinglechainfragmentvariable,ScFvSingledomainantibodyMinimalrecognitionantibody,MRUbispecificantibodyGeneticengineeringantibodyRearrangementofIggenesandsynthesisofIgTheNobelPrizeinPhysiologyorMedicine1987"forhisdiscoveryofthegeneticprincipleforgenerationofantibodydiversity"SusumuTonegawa
ⅡRearrangementofIggenesandsynthesisofIgOrganizationofIggenelociThreeseparatelociencode,respectively,alltheIgheavychains,theIgκlightchain,andtheIgλlightchain.Eachlocusisonadifferentchromosome.RearrangementofVregionofIgmoleculeMechanismsofV(D)JRecombinationV(D)JRecombinase:Rag-1/Rag-2Recombinationsignalsequences(RSS)RSS=heptamer+spacer+nonamer12/23ruleLoopingoutandinversionConservedheptamer(7bp)andnonamer(9bp)sequences,separatedby12-or23-bpspacers,arelocatedadjacenttoVandJexons(forκandλloci)ortoV,D,andJexons(intheHchainlocus).TheV(D)Jrecombinaserecognizestheserecombinationsignalsequencesandbringstheexonstogether
ProcessofV(D)JrecombinationConsequencesofVDJrecombinationIggenerecombinationandexpressionAllelicexclusionandIsotypeexclusionIggenerecombinationandexpressionⅢGenerationofDiversityofIgDiversity
(repertoire)isthetotalofalltheAbspecificitiesthatanorganismiscapableofexpressing.History-Germlinetheory-SomaticmutationⅢGenerationofDiversityofIgCurrentconceptsCombinatorialdiversity
V-D-J-CorV-J-CH-LJunctionaldiversity
P-nucleotideN-regioninsertionSomatichypermutation
antigenstimulation
CombinatorialdiversityJunctionaldiversityJunctionaldiversitySomatichypermutationⅣApplicationofAbScientificresearchDiagnosisTherapyProphylaxisClinicaltherapyTheNobelPrizeinPhysiologyorMedicine1901"forhisworkonserumtherapy,especiallyitsapplicationagainstdiphtheria,bywhichhehasopenedanewroadinthedomainofmedicalscienceandtherebyplacedinthehandsofthephysicianavictoriousweaponagainstillnessanddeaths"EmilvonBehring(1845-1917)腫瘤靶向治療的單克隆抗體商品名英文名靶點(diǎn)腫瘤類型赫賽汀HerceptinHER-2轉(zhuǎn)移性乳腺癌阿瓦斯汀Avastin血管內(nèi)皮生長因子非小細(xì)胞肺癌愛必妥ErbituxEGFR結(jié)直腸癌美羅華RituxanCD20淋巴瘤FDA批準(zhǔn)的抗腫瘤單抗和進(jìn)入臨床試驗(yàn)的單抗Numberofnovelanticancerantibodiesateachphaseofclinicaldevelopment.CTLA-4、PD-1與配體結(jié)合可導(dǎo)致T細(xì)胞對腫瘤的殺傷減弱,T細(xì)胞功能耗竭
靶向負(fù)性免疫調(diào)節(jié)分子的抗體藥物(靶向T細(xì)胞的負(fù)性共刺激分子)Targetimmunecheckpoint(CTLA-4,PD-1,PD-L1……)阻斷共抑制分子信號能逆轉(zhuǎn)T細(xì)胞的抑制狀態(tài)激活抗腫瘤免疫Ipilimumab(Yervoy)CTLA-4:Down-regulatesT-cellactivationIpilimumab(Yervoy):FullyhumanmonoclonalantibodyBlocksCTLA-4receptorPotentiatesTcellactivationKorman,PeggsandAllison:Adv.InImmunol.2006;90:297-339Ipilimumab:MechanismofActionTcellTCRCTLA4APCMHCB7T-cellinhibitionTcellTCRCTLA4APCMHCB7T-cellactivationTcellTCRCTLA4APCMHCB7T-cellpotentiationIPILIMUMABblocksCTLA-4CD28CD28Anti-PD-1antibody
Nivolumab(BMS-936558)Safety&activityTopalianSLetal.NEJM2012;366:2443Docetaxelvsnivolumab:phase3Lambrolizumab(MK-3475)Anti-PD-L1antibodyBMS-936559Safety&activityBrahmerJRetal.NEJM2012;366:2455Medi-4736MPDL-3280AAnti-PD-1,PD-L12014年11月,在同一期Nature上發(fā)表了5篇文章和1篇述評,研究內(nèi)容都是免疫抑制性分子的單抗(anti-PD-L1,anti-PD-1,anti-CTLA4,anti-CD40)在腫瘤免疫治療中的作用Nivolumab和ipilimumab聯(lián)合治療黑色素瘤NEJM2013;369(2):122-33CTLA-4和PD-1單抗聯(lián)合治療1例惡性黑色素瘤NEnglJMed.2015休息一下!Cytokines,CKsCytokinesConceptCharacteristicsClassificationCytokinereceptorBiologicactivityIntroductiontocytokinesWhatarecytokines
?
Cytokinesaresmallproteinsthataresecretedbycellsandexerttheirbiologicalactivitythroughspecificcellsurfacereceptors.
IntroductiontocytokineIntroductiontocytokineDifferfromgrowthfactorsthatcytokines
involvedinhostdefensethatactonwhitebloodcells(leukocytes),
whereasgrowthfactorsactonothersomaticcelltypes.Differfromgrowthfactorsthatareproducedconstitutively,whilecytokineproductioniscarefullyregulated
IntroductiontocytokineNomenclaturemonokine,LymphokinecolonystimulatingfactorInterleukinInterferontumornecrosisfactorgrowthfactorchemokineIntroductiontoCKsGeneralpropertiesofCKs
1.Smallproteins(MW:approx.15-30KD);2.Extremelypotent,actingatpMorfM3.Theproductionistransientandtightlyregulated;4.Autocrine,paracrineorendocrine;5.Non-specificandnon-MHCrestriction;6.DiversityinactionsCytokinescanactinthreedifferentmannersAutocrine:IL-2CytokinebindstoreceptoroncellthatsecreteditParacrine:IL-12CytokinebindstoreceptorsonnearbycellsEndocrine:IL-1CytokinebindscellsindistantpartsofthebodyIntroductiontoCKs
CytokineActions
Pleiotropy:Actonmorethanonecelltype(IFN-α/β)Redundancy:Morethanonecytokinehavethesameaction(IFN-α/βandIFN-γ)IntroductiontoCKs
CytokineActions
Synergy:TwoormoreCKscooperatetoproduceaneffectthatisdifferentorgreaterthanthecombinedeffectofthetwocytokineswhenfunctioningseparately(IL-12andIL-18)Antagonism:Twoormorecytokinesworkagainsteachother(IL-4andIL-12)IntroductiontoCKs
CytokineActions
Cytokinecascade
Acytokinemayincrease(ordecrease)theproductionofanothercytokineIntroductiontocytokineTheCKsnetworkIthasbeenshownabovethattherearemanyCKswithmultiplefunctionsandapparentredundancyofactionformingacomplexcommunicationnetwork.Figure:cytokinesnetworkHowcannon-specificcytokinesactspecifically?OnlycellsexpressingreceptorsforspecificcytokinescanbeactivatedbythemManycytokineshaveveryshorthalf-livesOnlycellsincloseproximitywillbeactivatedHighconcentrationsofcytokinesareneededforactivationOnlycellsincloseproximitywillbeactivatedMayrequirecell-tocellcontactCategoriesofCKsInterleukin(IL)Interferon(IFN)Tumornecrosisfactor(TNF)Colonystimulatingfactor(CSF)ChemokineGrowthfactor(GF)
Cytokinereceptor(CKR)1.FivefamiliesIgsuperfamilyreceptorsClassIcytokinereceptorfamilyClassⅡcytokinereceptorfamilyClassⅢcytokinereceptorfamily(TNFreceptorfamily)ChemokinereceptorfamilyCKreceptorMulti-subunitreceptor
oneforcytokinebindinganotherforcytokinesignalingCommonreceptorsubunitThereissamereceptorsubunitforcytokinesignalingamongthedifferentcytokinereceptors.e.g.IL-2Rγ
CKReceptorDavidPhillipVetter(September21,1971–February22,1984)wasaboyfromShenandoah,Texas,UnitedStateswhosufferedfromararegeneticdiseasenowknownasseverecombinedimmunedeficiencysyndrome(SCIDS).SignalTransductionbycytokinereceptorsCytokinereceptorsondifferentcelltypestriggerdifferenteventsinterleukin,ILIL1~37IL-2(Tcellgrowthfactor)IL-4(Th2type)IL-6(Bcellgrowthfactor,Th2type)IL-8(chemokine)IL-10(Th2type)IL-11(stimulatorofplatelet)IL-12(Th1type)IL-2TheschematicstructureoftheIL-2receptorsubunitsIL-4IL-12interferon,IFNIFNsmediatetheearlyinnateimmuneresponse;groupstypeIIFN:IFN-αandIFN-β.Themajorsourceisleukocyte,fibroblastsandvirusinfectedcells;typeIIIFN:IFN-γ.IFN-γismainlyproducedbyactivatedTcellsandNKcells.InterferonActionViralreplicationstimulatestheinfectedhostcelltoproduceinterferon.InterferoninducesuninfectedcellstoproduceantiviralproteinsthatpreventtranslationofviralmRNAdegradeviralnucleicacidViralreplicationisblockedinuninfectedcellsTumornecrosisfactor,TNFTNF:causethenecrosisoftumorsTNF-αandTNF-β.TNF-αwasproducedbyLPS-stimulatedmononuclearphagocytesandactivtedTcells;TNF-β:alsotermedaslymphotoxin(LT),andthemajorsourceisactivatedTcells.Colony-stimulatingfactor,CSFStimulatingthedifferentiationandexpansionofbonemarrowprogenitor;beassayedbytheirabilitytostimulatetheformationofcellclonesinculture.IncludingIL-3,CSF(G-CSF,M-CSF,GM-CSF),SCF,EPO,TPO,etc.ChemokineChemokinesarealargefamilyofstructurallyhomologousCKsthatstimulatemovementandregulatethemigrationofleukocytesfromthebloodtotissues,includingabout50differentchemokines.subfamily:CXC,CC,C,CX3C,basedonstructuralcharacteristic(cysteineresidues).ChemokineIL-8CXCneutrophilsMCP-1CCmonocyteLymphotactinClymphocyteFractalkineCX3ClymphocyteGrowthfactor(GF)Promotingtheproliferationanddifferentiationofcells;IncludingTGF-
、EGF、VEGF、FGF、NGF、PDGF,etc.BiologicactionsofCKsMediateandregulateinnateimmunityMediateandregul
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025廠長勞動合同簽訂與勞動爭議調(diào)解協(xié)議4篇
- 2025年度體育設(shè)施承包經(jīng)營協(xié)議范本3篇
- 二零二五新春企業(yè)復(fù)工環(huán)境保護(hù)合同2篇
- 2025年度環(huán)保型產(chǎn)品宣傳冊創(chuàng)意設(shè)計(jì)制作服務(wù)合同4篇
- 2025年廠房租賃合同智能化管理版4篇
- 個人二手車輛交易合同2024年專用
- 2025年度文化遺產(chǎn)地拆遷產(chǎn)權(quán)保護(hù)協(xié)議4篇
- 2025年度智能安防產(chǎn)品委托設(shè)計(jì)合同4篇
- 2025不動產(chǎn)交易擔(dān)保合同范本3篇
- 兩地研學(xué)合作協(xié)議合同范本 2篇
- GB/T 12494-1990食品機(jī)械專用白油
- 運(yùn)輸供應(yīng)商年度評價表
- 成熙高級英語聽力腳本
- 北京語言大學(xué)保衛(wèi)處管理崗位工作人員招考聘用【共500題附答案解析】模擬試卷
- 肺癌的診治指南課件
- 人教版七年級下冊數(shù)學(xué)全冊完整版課件
- 商場裝修改造施工組織設(shè)計(jì)
- (中職)Dreamweaver-CC網(wǎng)頁設(shè)計(jì)與制作(3版)電子課件(完整版)
- 統(tǒng)編版一年級語文上冊 第5單元教材解讀 PPT
- 加減乘除混合運(yùn)算600題直接打印
- ASCO7000系列GROUP5控制盤使用手冊
評論
0/150
提交評論